Featured Research

from universities, journals, and other organizations

Blocking an inflammation pathway prevents cardiac fibrosis, study suggests

Date:
March 22, 2013
Source:
University of California - Davis Health System
Summary:
New research shows that blocking an enzyme that promotes inflammation can prevent the tissue damage following a heart attack that often leads to heart failure.

New research from UC Davis published in the Proceedings of the National Academy of Sciences shows that blocking an enzyme that promotes inflammation can prevent the tissue damage following a heart attack that often leads to heart failure.

Led by Nipavan Chiamvimonvat, cardiologist and professor of internal medicine, a team of researchers tested a compound that inhibits the enzyme soluble epoxide hydrolase -- or sEH -- one of the key players in the robust immune-system response that heals tissue following an injury. The enzyme, however, can become counterproductive after a cardiac event.

Chiamvimonvat explained that sEH increases proinflammatory lipid mediators, leading to long-term, heightened inflammatory conditions. It also causes cells, which typically link together and provide the foundation for heart tissue, to overwork. The outcome is scar tissue, or fibrosis, that results in an abnormal relaxation of the heart after each beat, taxing remaining heart muscle as it performs double duty and eventually leading to a decline in the heart's pumping action.

"We often see patients following a heart attack in clinic who initially respond well to current treatments, which address the initial causes of the cardiac event and try to preserve heart function," said Chiamvimonvat, whose research focuses on the biological mechanisms of heart disease. "Over time, though, heart function in some patients continues to worsen and can lead to heart failure. It would be ideal to have new approaches that target the cellular overproduction that leads to heart muscle stiffening and cardiac fibrosis."

Heart failure progressively limits oxygen throughout the body, reducing mobility, respiration and quality of life. According to the Centers for Disease Control and Prevention, the condition affects 5.7 million people in the U.S. and costs the nation $34.4 billion in health-care services, medications and lost productivity. About half of people who have heart failure die within five years of diagnosis.

Previous research by Chiamvimonvat showed that an sEH inhibitor synthesized in the laboratory of entomology Professor Bruce Hammock can reduce the enlargement of heart muscle cells and associated arrhythmia. For the current study, she conducted a series of experiments to determine if it could also be a potential treatment for fibrosis.

Chiamvimonvat and her team tested the compound on a mouse model for heart attack. Because cardiac fibrosis can also be caused by other long-term cardiac diseases, the compound was also used on a mouse model for the chronic pressure overload commonly seen with hypertension. For both models, one group of mice was given the compound with their drinking water, while another group was not. The animals' heart functions were assessed using echocardiography.

The results showed that the mice receiving treatment had significant decreases in adverse cardiac muscle remodeling following a heart attack or due to chronic pressure overload. Their overall cardiac function also improved. Additional tests performed in Hammock's lab showed significantly reduced inflammatory factors in their systems.

"Our study shines new light on this inflammation pathway and identifies a potential therapeutic target that could greatly expand options for one of the biggest and most difficult-to-treat problems in cardiology," said Javier Lopez, cardiologist, assistant professor of internal medicine and study co-author who developed methods used in the study to quantify fibrotic cells.

The team hopes to test the compound next on a larger animal model as a precursor to human clinical trials.

"This project is part of a long-term, exciting collaboration between two labs dedicated to combining their strengths to benefit human health," said Hammock. "The translational value of our research is significant."

The study received major support from the National Institutes of Health (grant HL85727 and HL85844), a Veterans Administration Merit Review Grant, the Howard Hughes Medical Institute Med-into-Grad Training Program, an NIH-funded Training Grant in Basic and Translational Cardiovascular Science (grant T32 HL86350), the American Heart Association, a Western States Affiliate Predoctoral Fellowship Award, a Fellow-to-Faculty Award from the Sarnoff Cardiovascular Research Foundation and a Harold Amos Medical Faculty Development Award from the Robert Wood Johnson Foundation.

Partial support was provided by the National Institute of Environmental Health (grant R37 ES01710), the NIEHS Superfund Basic Research Program (grant P42 ES04699), the NIEHS Center for Children's Environmental Health and Disease Prevention (grant P02 ES11269), a Technology Translational Grant from UC Davis Health System and the American Asthma Society. Hammock is a George and Judy Marcus Senior Fellow of the American Asthma Society. Chiamvimonvat is also affiliated with the VA Northern California Healthcare System.

Additional UC Davis study authors were Padmini Sirish, Ning Li, Jun-Yan Liu, Kin Sing Stephen Lee, Sung Hee Hwang, Hong Qiu and Siu Mei Ma. Author Cuifen Zhao is currently at Shandong University in China.


Story Source:

The above story is based on materials provided by University of California - Davis Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. P. Sirish, N. Li, J.-Y. Liu, K. S. S. Lee, S. H. Hwang, H. Qiu, C. Zhao, S. M. Ma, J. E. Lopez, B. D. Hammock, N. Chiamvimonvat. Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis. Proceedings of the National Academy of Sciences, 2013; DOI: 10.1073/pnas.1221972110

Cite This Page:

University of California - Davis Health System. "Blocking an inflammation pathway prevents cardiac fibrosis, study suggests." ScienceDaily. ScienceDaily, 22 March 2013. <www.sciencedaily.com/releases/2013/03/130322104304.htm>.
University of California - Davis Health System. (2013, March 22). Blocking an inflammation pathway prevents cardiac fibrosis, study suggests. ScienceDaily. Retrieved August 28, 2014 from www.sciencedaily.com/releases/2013/03/130322104304.htm
University of California - Davis Health System. "Blocking an inflammation pathway prevents cardiac fibrosis, study suggests." ScienceDaily. www.sciencedaily.com/releases/2013/03/130322104304.htm (accessed August 28, 2014).

Share This




More Health & Medicine News

Thursday, August 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Director On Ebola Outbreak: 'It's Worse Than I Feared'

CDC Director On Ebola Outbreak: 'It's Worse Than I Feared'

Newsy (Aug. 28, 2014) CDC director Tom Frieden says the Ebola outbreak is even worse than he feared. But he also said there's still hope to contain it. Video provided by Newsy
Powered by NewsLook.com
Treadmill 'trips' May Reduce Falls for Elderly

Treadmill 'trips' May Reduce Falls for Elderly

AP (Aug. 28, 2014) Scientists are tripping the elderly on purpose in a Chicago lab in an effort to better prevent seniors from falling and injuring themselves in real life. (Aug.28) Video provided by AP
Powered by NewsLook.com
Japan's Golden Generation Shows No Sign of Slowing Down

Japan's Golden Generation Shows No Sign of Slowing Down

AFP (Aug. 27, 2014) For many people in the autumn of their lives, walking up stairs is the biggest physical challenge they face. But in Japan, race tracks, hammer or pole vault await competitors at the Kyoto Masters, some of them more than 100 years old. Duration: 02:32 Video provided by AFP
Powered by NewsLook.com
Mini Pacemaker Has No Wires

Mini Pacemaker Has No Wires

Ivanhoe (Aug. 27, 2014) Cardiac experts are testing a new experimental device designed to eliminate major surgery and still keep the heart on track. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins